Current treatment algorithm for the management of lower-risk MDS

A Giagounidis - Hematology 2014, the American Society of …, 2017 - ashpublications.org
A Giagounidis
Hematology 2014, the American Society of Hematology Education …, 2017ashpublications.org
Lower risk myelodysplastic syndromes (MDS), defined as MDS with a Revised International
Prognostic Scoring System score≤ 3.5 points, will remain a challenging entity in 2018.
Supportive care continues to be the linchpin of treatment, although the options to reduce
transfusion needs are broadening. To achieve red blood cell transfusion independence in
non-del (5q) patients, erythropoiesis-stimulating agents remain a mainstay of therapy as
long as endogenous erythropoietin levels are< 500 U/L (and preferably< 200 U/L) …
Abstract
Lower risk myelodysplastic syndromes (MDS), defined as MDS with a Revised International Prognostic Scoring System score ≤3.5 points, will remain a challenging entity in 2018. Supportive care continues to be the linchpin of treatment, although the options to reduce transfusion needs are broadening. To achieve red blood cell transfusion independence in non-del(5q) patients, erythropoiesis-stimulating agents remain a mainstay of therapy as long as endogenous erythropoietin levels are <500 U/L (and preferably <200 U/L). Experimental strategies for patients ineligible for erythropoiesis-stimulating agents or relapsing after gaining transfusion independence include immunosuppressive agents, transforming growth factor β inhibitors, and lenalidomide. All these alternatives have shown reasonable response rates in selected patient populations with lower risk MDS. Patients with del(5q) disease can derive long-term benefit from lenalidomide, and some patients remain transfusion free for extended periods even after discontinuation of the drug. In rare cases in which thrombocytopenia is the main clinical problem leading to clinically significant bleeding events, thrombopoietin receptor analogues may alleviate bleeding, increase platelet counts, and rarely lead to trilineage responses. It seems prudent to use these drugs only in patients with confirmed bone marrow blast counts <5%. Allogeneic stem cell transplantation is reasonable for patients with high molecular risk of progression and those failing several lines of treatment with signs of progression toward higher-risk MDS.
ashpublications.org